Shanghai Novamab Biopharmaceuticals Co., Ltd.

Shanghai Novamab Biopharmaceuticals Co., Ltd is an innovative biopharmaceutical company dedicated to the development of novel nanobody drugs for patients all over the world. It was established in 2017, and now has more than 90 full time employees. Novamab is the first corporation in China that had a CMC process development platform of Pichia pastoris. Novamab has established the first platform for nanobody drug inhalation and delivery in China. In Sept. 2020, Novamab successfully passed the recognition of high-tech enterprises in Shanghai, becoming a "high-tech enterprise". Novamab has developed more than 10 nanobody drugs pipeline covering respiratory, anti-infection, ophthalmology and oncology. An inhalable candidate for asthma treatment was under clinical investigation both in Australia and China. Another nanobody drug for both Th2-low and Th2-high asthma and COPD has received clinical approval document.